RPL7P48: A Ribosomal Protein L7 Pseudogene for Drug Targets and Biomarkers

Target Name: RPL7P48

NCBI ID: G388401

RPL7P48

Other Name(s): ribosomal protein L7 pseudogene 48 | Ribosomal protein L7 pseudogene 48 | RPL7_19_1558

RPL7P48: A Ribosomal Protein L7 Pseudogene for Drug Targets and Biomarkers

Ribosomal proteins (RPs) are a family of large proteins that form the nucleotide-binding proteins (NBP) complex, which plays a critical role in protein synthesis. Ribosomal proteins are encoded by the RPL genes, which are located on the X chromosome. The genes encoding RPs can differ in their amino acid sequences, leading to the development of different isoforms. In this article, we will focus on RPL7P48, a pseudogene associated with ribosomal protein L7 (RPL7), and its potential as a drug target or biomarker.

Expression and Localization

RPL7 is a highly conserved protein that is involved in various cellular processes, including protein synthesis, DNA replication, and repair, as well as cell signaling. It is composed of 198 amino acids and has a molecular weight of 21 kDa. RPL7 is expressed in most tissues and cells, including muscle, heart, brain, and cancer cells. It is also found in the nucleoplasm and in the cytoplasm of these cells.

RPL7P48 is a pseudogene that is located on the X chromosome at position 48 on the gene. It is a single exon gene that encodes a protein with 198 amino acids. The protein has a molecular weight of 21 kDa and is composed of 11 unique amino acids. RPL7P48 is predominantly expressed in the nucleoplasm of human cells, with lower levels detected in the cytoplasm.

Function and Interaction

RPL7P48 is a part of the RPL7 gene family and is involved in the formation of the RPL7 protein. RPL7 is a key regulator of protein synthesis in eukaryotic cells, and it functions as a protein-protein interaction (PPI) partner for various transcription factors, including activator protein 1 (AP-1), transcription factor-regulated intron retention (TFI) factor 1 (TIF1), and RNA polymerase II (RNA-II).

RPL7P48 functions as a protein-protein interaction (PPI) partner for various transcription factors, including activator protein 1 (AP-1), transcription factor-regulated intron retention (TFI) factor 1 (TIF1), and RNA polymerase II (RNA-II). These interactions play a crucial role in the regulation of gene expression and protein synthesis.

Drug Targets and Biomarkers

RPL7P48 has been identified as a potential drug target due to its involvement in various cellular processes. Several studies have shown that RPL7P48 can be targeted by small molecules, including inhibitors of protein synthesis and tyrosination. These inhibitors have been shown to induce apoptosis (programmed cell death) in RPL7-deficient cells, suggesting that targeting RPL7P48 may be a promising strategy for cancer treatment.

In addition to its potential as a drug target, RPL7P48 has also been shown to be a potential biomarker for various diseases, including cancer. The expression of RPL7 is known to be elevated in various types of cancer, including breast, ovarian, and colorectal cancers. This increased expression of RPL7 may serve as a potential biomarker for these diseases.

Conclusion

RPL7P48 is a pseudogene associated with the RPL7 protein that is expressed in most tissues and cells. It is a potential drug target due to its involvement in various cellular processes and its ability to interact with various transcription factors. Additionally, it has been shown to be a potential biomarker for various diseases, including cancer. Further research is needed to fully understand the role of RPL7P48 in

Protein Name: Ribosomal Protein L7 Pseudogene 48

The "RPL7P48 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL7P48 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets